Novel Therapies for Chronic Inflammatory Diseases and Autoimmune Diseases

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 540

Special Issue Editor


E-Mail Website
Guest Editor
International Society of Engineering Science and Technology, Nottingham, UK
Interests: diabetes; stem cells; autoimmune dieseases; nanotechnology

Special Issue Information

Dear Colleagues,

Chronic inflammatory illnesses and autoimmune disorders represent a major global health issue, characterised by persistent inflammation and immunological dysregulation, which can cause severe tissue damage and a lower quality of life. Despite advances in immunomodulatory therapy, current medications frequently have limited efficacy and serious adverse effects, emphasising the need for innovative therapeutic methods. This Special Issue will investigate cutting-edge solutions in the prevention and treatment of chronic inflammatory and autoimmune illnesses, with an emphasis on molecular and cellular advances. A focus will be placed on innovative biologics, small-molecule inhibitors, gene editing technologies, and cell-based therapeutics such as mesenchymal stem cells and modified immune cells that target key inflammatory pathways. Furthermore, this Special Issue will investigate the effect of gut microbiota manipulation, nanoparticle-based drug delivery methods, and personalised medicine techniques in improving therapy specificity and patient outcomes. Contributions that investigate the molecular pathways underlying disease aetiology, biomarker identification for early diagnosis, and clinical trial data on developing therapeutics are also welcome. Our aim is to create a comprehensive forum where academics and doctors can share recent progress, with the ultimate goal of transforming new research into better and safer therapeutic alternatives for patients. This Special Issue will promote interdisciplinary collaboration and close the gap between basic research and clinical applications in the field of chronic inflammatory and autoimmune disease management.

Dr. Emina Karahmet Sher
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic inflammatory diseases
  • autoimmune diseases
  • biomarker identification
  • innovative biologics
  • small-molecule inhibitors
  • gene editing technologies
  • cell-based therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 893 KiB  
Article
The Impact of Surgery on Quality of Life in Hidradenitis Suppurativa: Results from a Prospective Single-Center Study
by Lennart Ocker, Nessr Abu Rached, Anna Koller, Carolin Frost, Riina Käpynen and Falk G. Bechara
Life 2025, 15(5), 769; https://doi.org/10.3390/life15050769 - 12 May 2025
Viewed by 271
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that severely impairs quality of life. Treatment typically involves a patient-oriented combination of medical therapies, surgery, and lifestyle modifications. However, data on the impact of surgical treatments on quality of life remain limited. This [...] Read more.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that severely impairs quality of life. Treatment typically involves a patient-oriented combination of medical therapies, surgery, and lifestyle modifications. However, data on the impact of surgical treatments on quality of life remain limited. This prospective monocentric study aimed to evaluate the effect of wide surgical excision in patients with moderate to severe HS (Hurley stage II/III) who were naïve to systemic biologic treatments. Between March 2017 and November 2022, 82 patients (51% female; 80% Hurley II, 20% Hurley III) underwent major surgical excision. Assessments were performed before surgery and at three and six months postoperatively. The primary endpoint was the change in Dermatologic Life Quality Index (DLQI); secondary endpoints included changes in pain (NRS-11) and disease severity scores. DLQI improved from 11.7 at baseline to 8.3 at three months and 4.7 at six months (p < 0.001). Pain scores and the modified Hidradenitis Suppurativa Score (mHSS) also significantly decreased (p < 0.001). In conclusion, major surgery significantly improved quality of life and pain in HS patients, confirming its essential role in a multimodal treatment approach. Patient-reported outcome measures are crucial for assessing treatment efficacy in HS. Full article
Show Figures

Figure 1

Back to TopTop